Exelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: EXEL
- CUSIP: 30161Q10
- Previous Close: $23.12
- 50 Day Moving Average: $19.16
- 200 Day Moving Average: $14.96
- 52-Week Range: $3.55 - $23.49
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 256.78
- P/E Growth: 2.14
- Market Cap: $6.62B
- Outstanding Shares: 286,455,000
- Beta: 1.78
- Net Margins: -123.81%
- Return on Assets: -30.16%
Companies Related to Exelixis:
- Debt-to-Equity Ratio: 2.54%
- Current Ratio: 2.09%
- Quick Ratio: 2.07%
What is Exelixis' stock symbol?
Exelixis trades on the NASDAQ under the ticker symbol "EXEL."
Where is Exelixis' stock going? Where will Exelixis' stock price be in 2017?
6 equities research analysts have issued 1-year price objectives for Exelixis' stock. Their predictions range from $8.00 to $17.00. On average, they expect Exelixis' stock price to reach $14.11 in the next twelve months.
When will Exelixis announce their earnings?
Exelixis is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
What are analysts saying about Exelixis stock?
Here are some recent quotes from research analysts about Exelixis stock:
According to Zacks Investment Research, "Exelixis received a major boost with the FDA approval of Cabometyx tablets in April. Initial uptake of the drug was encouraging and is expected to propel the top line in the forthcoming quarters. Meanwhile, Cabometyx also received approval in the EU in September, which triggered a milestone payment of $60 million to Exelixis. The product will be marketed in the EU by Exelixis’ partner, Ipsen. Moreover, Exelixis is developing cabozantinib in a broad development program comprising over 45 clinical studies across multiple indications. Moreover, successful commercialization of the other marketed drug, Cotellic in the U.S. will boost the top line. Exelixis’ share price has outperformed the Zacks classified Biomedical and Genetics industry in the last one year driven by the approval of Cabometyx. However, expenses are expected to increase as the company continues the commercialization of the drug for newer indications." (2/6/2017)
Leerink Swann analysts commented, "We view today’s better than expected 2Q revenue preannouncement as a positive step as XENT works through some sales force restructuring/turnover related issues that have impacted the company since late-2015. The better than expected preliminary top- line results suggest business momentum is picking up. We continue to believe stock performance from here is tied to mgmt’s ability to hire new reps and drive higher sales force productivity. 2Q preliminary revenue of $19.3M ahead of consensus. XENT beat the Street/us by ~3%, which we think is a positive sign on mgmt’s ability to execute following a surprise in-line 1Q. We think expectations were for an in-line 2Q and are encouraged that some of the disruptions in 1Q may be in the rear-view mirror, and it appears that Propel Mini is beginning to generate positive momentum. The company also hired one rep more than what we were projecting (now have 73 territory managers vs. our 72 est) and rep productivity was slightly above our forecast ($1.10M/rep vs. $1.07M/rep est.)." (7/19/2016)
Who owns Exelixis stock?
Exelixis' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (14.98%), State Street Corp (2.64%), Two Sigma Investments LP (1.59%), Janus Capital Management LLC (0.70%), Renaissance Technologies LLC (0.46%) and Bogle Investment Management L P DE (0.42%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, George A Scangos, Gisela Schwab, Lance Willsey and Peter Lamb.
Who sold Exelixis stock? Who is selling Exelixis stock?
Exelixis' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Janus Capital Management LLC, Renaissance Technologies LLC, Marshall Wace LLP, Oxford Asset Management, Castleark Management LLC, Graham Capital Management L.P. and Guggenheim Capital LLC. Company insiders that have sold Exelixis stock in the last year include Alan M Garber, Carl B Feldbaum, George A Scangos, Gisela Schwab and Peter Lamb.
Who bought Exelixis stock? Who is buying Exelixis stock?
Exelixis' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Two Sigma Investments LP, Franklin Resources Inc., Alyeska Investment Group L.P., Russell Investments Group Ltd., Dimensional Fund Advisors LP, Nicholas Investment Partners LP and Allianz Asset Management AG.
How do I buy Exelixis stock?
Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Exelixis stock cost?
One share of Exelixis stock can currently be purchased for approximately $23.11.